Figure 7. IL-33 signaling in tumor-associated DCs requires MyD88 and STAT1.

(A) rIL-33 increased the number of B16-SIY-infiltrating Gr-1⁻CD11b⁺CD11c⁺ DCs from WT but not MyD88^−/− mice (n=5). (B) Representative flow cytometry analysis of frequency of CD40, CD80, CD86, or MHC-II in DCs from DLNs of WT or MyD88^−/− tumor-bearing mice (n=5) killed 8-10 d after PBS or rIL-33 treatment. Internal controls were gated from cell populations within the analyzed sample that do not express DC costimulatory molecules. (C) Gr1⁻CD11c⁺ DCs from DLNs of tumor-bearing WT mice were rested overnight and then stained intracellularly for phosphorylated STAT1 by flow cytometry. (D) Representative flow cytometry analysis of phosphorylated STAT1 and ST2 by gated CD11b⁺CD11c⁺ DCs from DLNs of rIL-33-treated tumor-bearing WT or MyD88^−/− mice. *; p<0.05, **; p<0.01, ***; p<0.001. Data (mean ± SEM) are representative of 3 independent experiments.